+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
R

Actively Recruiting

Researchers are conducting a randomized controlled trial to compare survival outcomes between robotic-assisted laparoscopy and open hysterectomy with lymph node assessment for early-stage cervical cancer. The study aims to determine if robotic hysterectomy with tumor containment before colpotomy is not worse than abdominal hysterectomy in terms of disease-free survival. It includes patients with specific cervical cancer stages and tumor sizes suitable for surgery. Participants will undergo either a radical or simple hysterectomy using either traditional open surgery or a robotic-assisted technique. In the robotic group, the vagina is closed before colpotomy, and certain vaginal manipulators are not allowed. Both groups may have salpingectomy and oophorectomy with or without ovarian transposition. Surgeons will document operative details, including any complications, blood loss, and reasons for conversion to open surgery. During the trial, participants will be closely monitored with preoperative assessments like labs, EKG, and MRI to confirm eligibility. Surgical findings and complications will be recorded. The primary outcome measured is survival at 36 months. Participants must provide informed consent and undergo follow-up to assess disease status and survival over the study period, which extends until 2030.

Age: 18Years +FEMALEPhase Not Applicable
156 locations
B

Actively Recruiting

Researchers are evaluating the effects of combining two drugs, cabozantinib and nivolumab, in treating patients with advanced melanoma or squamous cell head and neck cancer that may have spread to nearby tissues, lymph nodes, or distant parts of the body. This phase II study aims to assess how quickly patients can be grouped based on tumor biomarkers called tumor mutational burden and tumor inflammation signature, and to learn if the combination can shrink or stabilize the cancer depending on these biomarker statuses. Participants receive nivolumab through an intravenous infusion on the first day of each 28-day treatment cycle and take cabozantinib orally daily. Treatment cycles continue for up to two years unless the cancer progresses or unacceptable side effects occur. Throughout the trial, patients undergo CT or MRI scans and blood sample collections. Tumor biopsies are taken during screening and optionally during follow-up. After completing treatment, participants are followed up every 12 weeks for one year and then every six months up to three years after registration. During the study, patients will be monitored with imaging scans and laboratory tests to assess tumor response and safety. Researchers will measure how quickly biomarker results are available and evaluate overall response rates, disease control, progression-free survival, and overall survival over two years. Safety and tolerability of the drug combination will also be assessed, along with the identification of biomarkers that might predict treatment response or side effects. Specimens will be collected and stored for future research.

Age: 18Years +All GendersPhase 2
232 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
P

Actively Recruiting

Researchers are studying vulnerable or older adults aged 70 and above with recurrent or metastatic non-small cell lung cancer NSCLC that has a PD-L1 tumor proportion score TPS less than 50%. The study aims to evaluate how often treatment-related side effects cause patients to stop chemotherapy when receiving a reduced dose of chemotherapy combined with immunotherapy. This is a phase 2, single-arm, open-label study assessing safety and tolerability in this specific patient group. Participants with squamous cell NSCLC will receive carboplatin and paclitaxel chemotherapy every 21 days for 4 cycles, while those with non-squamous NSCLC will receive carboplatin and pemetrexed on the same schedule. Both groups will receive pembrolizumab immunotherapy every 21 days for up to 35 cycles or until disease progression or unacceptable side effects occur. The first 4 cycles include chemotherapy plus immunotherapy, followed by maintenance immunotherapy alone from cycle 5 onward. During the study, participants will be closely monitored for treatment side effects, response to therapy, survival outcomes, and quality of life at multiple time points up to several years. Researchers will collect data on adverse events, disease progression, and cancer symptoms through scans, lab tests, and questionnaires. The primary outcome is the rate of chemotherapy discontinuation due to side effects over up to two years of treatment. Secondary outcomes include response rates, overall survival, progression-free survival, and symptom changes up to five years.

Age: 18Years +All GendersPhase 2
2 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether using the PAGODA algorithm to guide chemotherapy dose changes for the FOLFOX regimen reduces unplanned treatment delays in patients with digestive system cancers compared to usual care. This study focuses on cancers of the gastrointestinal tract, including esophagus, stomach, colon, rectum, and related sites, where FOLFOX chemotherapy is standard treatment. The trial compares dose adjustments made by the algorithm versus those made by clinicians based on standard assessments like blood tests and patient measurements. Participants receive FOLFOX chemotherapy involving oxaliplatin, folinic acid, and fluorouracil given intravenously. They are randomly assigned to either usual care, where clinicians decide on dose changes and delays during cycles 2 to 7, or the intervention arm, where the PAGODA algorithm guides these decisions with clinician oversight. After the treatment cycles, participants are followed up at 30 and 120 days, then annually for two years to monitor outcomes and safety. During the study, researchers track chemotherapy delays, dose changes, and safety measures such as neutropenia severity and relative dose intensity. Participants undergo regular blood tests and clinical assessments to evaluate these outcomes. The main measure is the rate of unplanned chemotherapy delays from cycles 2 to 7. Secondary measures include days spent in healthcare contact, occurrence of moderate-to-severe neutropenia, and chemotherapy dose intensity. This comprehensive monitoring continues through follow-up visits to assess the long-term impact of the dosing strategies.

Age: 18Years +All GendersPhase Not Applicable
398 locations
S

Actively Recruiting

Researchers are evaluating a new medicine called PF-08634404 to learn how it works when combined with other cancer medicines in people with advanced solid tumors that cannot be removed by surgery or cured with standard treatments. This study focuses on participants aged 18 and older who have advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. The study aims to assess the safety of PF-08634404 with other cancer medicines, observe possible side effects, and evaluate the treatments potential to help control these tumors. Participants will receive PF-08634404 combined with different anticancer agents during two main parts of the study. Part A tests PF-08634404 with Sigvotatug Vedotin, and Part B tests it with PF-08046054SGN-PDL1V. All study medicines are given through intravenous IV infusions at clinical trial sites, where trained medical staff will monitor participants during and after each visit. Throughout the study, participants will undergo regular assessments including monitoring for treatment-related side effects and serious adverse events up to 90 days after the last treatment. Researchers will also measure tumor response using imaging and clinical evaluations up to about five years. Additional tests will check laboratory abnormalities, drug levels in the blood, and immune responses to the medicine. Participants are monitored closely during visits to track safety and treatment effects.

Age: 18Years +All GendersPhase 1Phase 2
104 locations
P

Actively Recruiting

Researchers are evaluating the effects of adding sonrotoclax to zanubrutinib compared to zanubrutinib alone in treating patients with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Sonrotoclax is a BCL-2 inhibitor that may stop cancer cell growth by blocking a protein needed for their survival, while zanubrutinib is a kinase inhibitor targeting a protein present at abnormal levels in certain B-cell cancers. This phase III trial aims to compare progression-free survival and other outcomes between these therapies. Participants are randomly assigned to receive either zanubrutinib alone or zanubrutinib combined with sonrotoclax. Zanubrutinib is given orally twice daily every 28-day cycle. In the combination group, sonrotoclax is added once daily from cycle 4. After 14 cycles, patients with undetectable minimal residual disease MRD may stop therapy or continue based on their response, with some undergoing additional therapy cycles. Throughout treatment, patients undergo CT scans, bone marrow aspirations, and blood sample collections. Participants will be followed during treatment and after completion for up to 10 years, with visits every 3 months for the first 3 years, then every 6 months. Assessments include disease progression, survival, MRD status, response rates, toxicity, and patient-reported symptoms. Safety monitoring focuses on infections, cardiovascular events, tumor lysis syndrome, bleeding, cytopenias, and secondary cancers. The total duration of participation can extend through long-term follow-up and additional monitoring as needed.

Age: 65Years +All GendersPhase 3
261 locations

1-10 of 13

1